Stem cell therapy for transverse myelitis is an area of early research. Researchers are studying umbilical-cord-derived mesenchymal stromal cells, or UC-MSCs, because they may influence inflammation and immune signaling around injured nervous tissue.
What Researchers Are Studying
- Influence inflammatory and immune-system signaling
- Affect the environment around injured spinal cord tissue
- Be delivered safely and feasibly in carefully selected patients
- Support further study of motor, sensory, or autonomic changes
UC-MSCs release proteins and other signaling molecules that researchers are studying for their possible effects on inflammation and injured nervous tissue. These biological properties are one reason stem cell therapy for TM continues to be investigated as a potential regenerative approach.
Note: Stem cell therapies for transverse myelitis are not FDA-approved and are investigational. Direct human research is limited to a single case report involving surgery, secretome, UC-MSCs, and rehabilitation. The report provides early clinical information on this multi-component approach but cannot establish its safety or effectiveness.
How Stem Cell Therapy for TM Is Being Studied
Most regenerative medicine research related to TM remains early or indirect. Laboratory and animal studies may help researchers understand possible biological mechanisms, but they do not establish patient benefit. The available human case report involved posterior decompression surgery, mesenchymal stem cell-derived secretome, intrathecal umbilical-cord-derived mesenchymal stromal cells, and rehabilitation. This multi-component approach provides early clinical information for continued research.